Effect of amino acid ergot alkaloids on glutamate transport via human glutamate transporter hGluT-1

Journal of the Neurological Sciences

Volumn 155, Issue 1, 1998, Pages 31-36

  Yamashita, Hiroshi ^a   Kawakami, Hideshi ^a   Zhang, Yu Xiang ^a   Tanaka, Kohichi ^b   Nakamura, Shigenobu ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

Amino acid ergot alkaloid; Bromocriptine; Ergotamine; Glutamate transporter; HeLaS3 cells; hGluT 1

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BROMOCRIPTINE; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR; ERGOMETRINE; ERGOT ALKALOID; GLUTAMIC ACID; LISURIDE; OXIDOPAMINE; XANTHINE OXIDASE;

AMINO ACID SEQUENCE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; HELA CELL; HUMAN; HUMAN CELL; MICHAELIS CONSTANT; NEUROLOGIC DISEASE; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

AMINO ACID TRANSPORT SYSTEM X-AG; ANTIOXIDANTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BROMOCRIPTINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG ANTAGONISM; DRUG SYNERGISM; ERGOT ALKALOIDS; ERGOTAMINE; GLUTAMIC ACID; HELA CELLS; HUMANS; KINETICS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032542485     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(97)00266-9     Document Type: Article

References (27)

1. Bergman H., Wichmann T., DeLong M.R. Reversal of experimental antiparkinsonism by lesions of subthalamic nucleus. Science. 249:1990;1436-1438.
2. Calne D.B., Teychenne P.F., Claveria L.E., Eastman R., Greenacre J.K. Bromocriptine in parkinsonism. Br. Med. J. 4:1974;442-444.
3. Carlson M.D., Kish P.E., Ueda T. Glutamate uptake into synaptic vesicles: competitive inhibition by bromocriptine. J. Neurochem. 53:1989;1889-1894.
4. Euler T., Wassle H. Immunocytochemical identification of cone bipolar cells in the rat retina. J. Comp. Neurol. 36:1995;461-478.
5. Fairman W.A., Vandenberg R.J., Arriza J.L., Kavanaugh M.P., Amara S.G. An excitatory amino-acid transporter with properties of a ligand-gated chloride channel. Nature. 375:1995;599-603.
6. Fuxe K., Fredholm B.B., Agnati L.F.et al. Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders. Pharmacology. 16(Suppl 1):1978;99-134.
7. Hertz L. Functional interactions between neurons and astrocytes. I. Turnover and metabolism of putative amino acid transmitters. Prog. Neurobiol. 13:1979;277-323.
8. Kanai Y., Hediger M.A. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature. 360:1992;467-471.
9. Kartzinel R., Perlow M., Teychenne P.et al. Bromocriptine and levodopa (with and without carbidopa) in parkinsonism. Lancet. 2:1976;272-275.
10. Kawakami H., Tanaka K., Nakayama T., Inoue K., Nakamura S. Cloning and expression of a human glutamate transporter. Biochem. Biophys. Res. Commun. 199:1994;171-176.
11. Klockgether T., Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann. Neurol. 28:1990;539-546.
12. Liu X.H., Kato H., Chen T., Katou K., Itoyama Y. Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil. J. Neurol. Sci. 129:1995;9-14.
13. Markstein R. Neurochemical effects of some ergot derivatives: a basis for their antiparkinson action. J. Neural. Transm. 51:1981;49-59.
14. McBean G.L., Roberts P.J. Neurotoxicity of L-glutamate and DL-threo-3-hydroxyaspartate in the rat striatum. J. Neurochem. 44:1985;247-254.
15. Nakayama T., Kawakami H., Tanaka K., Nakamura S. Expression of three glutamate transporter subtype mRNAs in human brain regions and peripheral tissues. Mol. Brain Res. 36:1996;189-192.
16. Ogawa N., Tanaka K., Asanuma M.et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 657:1994;207-213.
17. Pines G., Danbolt N.C., Bjoras M.et al. Cloning and expression of a rat brain L-glutamate transporter. Nature. 360:1992;464-467.
18. Rall, T.W., 1990. Oxytocin, prostaglandins, ergot alkaloids, and other drugs. In: Gilmann, A.G., Rall, T.W., Nies, A.S., Taylor, P. (Eds.), The Pharmacological Basis of Therapeutics. Pergamon Press, New York, pp. 933-953.
19. Rothstein J.D., Jin L., Dykes-Hoberg M., Kuncl R. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA. 90:1993;6591-6595.
20. Sonsalla P.K., Nicklas W.J., Heikkila E. Role for excitatory amino-acids in metamphetamine-induced nigrostriatal dopaminergic toxicity. Science. 243:1988;398-400.
21. +-dependent glutamate/aspartate transporter from rat brain. Proc. Natl. Acad. Sci. USA. 89:1992;10955-10959.
22. Tanaka K. Expression cloning of a rat glutamate transporter. Neurosci. Res. 16:1993;149-153.
23. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418.
24. Yamashita H., Kawakami H., Zhang Y.X., Tanaka K., Nakamura S. Neuroprotective mechanism of bromocriptine. Lancet. 346:1995;1305.
25. Yamashita H., Kawakami H., Zhang Y.X., Hagiwara T., Tanaka K., Nakamura S. Inhibition by folded isomers of L-2-(carboxycyclopropyl)glycine of glutamate uptake via the human glutamate transporter hGluT-1. Eur. J. Pharmacol. 289:1995;387-390.
26. Yoshikawa T., Minamiyama Y., Naito Y., Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J. Neurochem. 62:1994;1034-1038.
27. Zerangue N., Arriza J.L., Amara S.G., Kavanaugh M.P. Differential modulation of human glutamate transporter subtypes by arachidonic acid. J. Biol. Chem. 270:1995;6433-6435.